Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 7:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 4 Interventional Results available

BLIS - Breastfeeding Levonorgestrel IUD Study

NCT01990703
Conditions
Contraception
Interventions
Levonorgestrel IUD
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Albuquerque, New Mexico • Salt Lake City, Utah
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Advance Supply of Emergency Contraception Compared to Routine Postpartum Care in Teens

NCT00433004
Conditions
Post Partum
Interventions
Plan B (Levonorgestrel)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
14 Years to 19 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

LARC Forward Contraceptive Counseling at MHCC

NCT02735551
Conditions
Contraception
Interventions
Long Acting Reversible Contraception (LARC), Referral for Long Acting Reversible Contraception (LARC), Prescription for Short-Acting Hormonal Contraception
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
17 Years to 30 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Gresham, Oregon
Conditions
EWINGS SARCOMA
Interventions
Rabbit anti-thymocyte globulin, Busulfan, Melphalan, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
University of Louisville
Other
Eligibility
Up to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Pregnancy Prevention
Interventions
Levonorgestrel 1.5mg, Meloxicam 15 mg, Placebo
Drug · Other
Lead sponsor
InnovaGyn, Inc.
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers Results available

Early vs. Interval Postpartum IUD Insertion

NCT03462758
Conditions
Contraception
Interventions
IUD
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
4
States / cities
La Jolla, California • San Diego, California • Chicago, Illinois + 1 more
Conditions
Estrogen Therapy
Interventions
Estrogen therapy, Mirena levonorgestrel-releasing intrauterine system, Other progestogen therapy
Drug · Device
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
456,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Ann Arbor, Michigan • Eden Prairie, Minnesota
Conditions
Pregnancy
Interventions
levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and condoms
Drug
Lead sponsor
University of Washington
Other
Eligibility
16 Years to 60 Years · Female only
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Completed Not applicable Interventional Accepts healthy volunteers Results available

Levonorgestrel Intrauterine System For Emergency Contraception

NCT01539720
Conditions
Pregnancy, Unplanned, Pregnancy; Accident
Interventions
Ulipristal acetate, levonorgestrel IUS
Drug · Device
Lead sponsor
Planned Parenthood of the St. Louis Region and Southwest Missouri
Other
Eligibility
14 Years to 45 Years · Female only
Enrollment
274 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia • Indianapolis, Indiana • St Louis, Missouri
Conditions
Contraception
Interventions
Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)
Device
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
16 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portsmouth, Virginia
Conditions
IUD, Contraceptive Implant, Contraception, Birth Control, Emergency Contraception
Interventions
Copper T-380 IUD, LNG IUD, Contraceptive implant Nexplanon, Depo-Provera
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
West Valley City, Utah
Completed Phase 4 Interventional Accepts healthy volunteers

Impact of Contraceptives on Cervico-Vaginal Mucosa

NCT04814927
Conditions
Mucosal Inflammation, Contraceptive; Complications, Intrauterine
Interventions
Copper IUD, Etonogestrel implant, Levonorgestrel IUS, DMPA Sub-cutaneous
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Norfolk, Virginia
Completed Phase 4 Interventional Accepts healthy volunteers Results available

'Levonorgestrel IUD Insertion After D&E Procedure

NCT00475228
Conditions
Contraceptive Usage
Interventions
Levonorgestrel IUD
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed No phase listed Observational Accepts healthy volunteers

Modulation of Immunity by Hormonal Contraceptives

NCT02011711
Conditions
Contraception
Interventions
Not listed
Lead sponsor
Thomas L. Cherpes
Other
Eligibility
15 Years to 25 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Stanford, California
Conditions
Epilepsy, Contraception
Interventions
levonorgestrel IUS
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Blood Coagulation Disorders
Interventions
Levonorgestrel-containing IUD (Mirena®), Copper-containing IUD (Paraguard®)
Device
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Burlington, Vermont
Conditions
Multiple Myeloma
Interventions
Siltuximab, Dexamethasone
Biological · Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
9
States / cities
Duarte, California • Norwalk, Connecticut • Indianapolis, Indiana + 6 more
Conditions
Healthy
Interventions
Levonorgestrel-releasing intrauterine system (LNG-IUS)
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Study of Ovulation in Obese Women

NCT06306131
Conditions
Pregnancy Prevention
Interventions
Levonorgestrel 1.5 milligram, Meloxicam 15 milligram, calcium carbonate 750 milligram
Drug · Other
Lead sponsor
InnovaGyn, Inc.
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effectiveness of Orally Dosed Emergency Contraception in Obese Women - LNG

NCT02863445
Conditions
Obesity
Interventions
Levonorgestrel-based emergency contraception 1.5 mg, Levonorgestrel-based emergency contraception 3.0mg
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Maintaining Intrauterine Devices (IUDs) in Teens (MINT): A Randomization Trial

NCT00653159
Conditions
Contraception
Interventions
Levonorgestrel-releasing intrauterine device (LNG-IUS), Copper T380A intrauterine device (CuT380A)
Device
Lead sponsor
University of Chicago
Other
Eligibility
14 Years to 18 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chicago, Illinois
Conditions
Weight Change
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
427 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Contraception
Interventions
Levonorgestrel IUD (LCS, BAY86-5028), Yasmin (EE30/DRSP, BAY86-5131)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 29 Years · Female only
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
24
States / cities
Tucson, Arizona • La Mesa, California • San Diego, California + 8 more
Conditions
Endometrial Hyperplasia
Interventions
BAY865028, Medroxyprogesterone acetate
Combination Product · Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
Phoenix, Arizona • Little Rock, Arkansas • West Hills, California + 19 more